Luminex Gets Canadian Approval for Drug Metabolism Genotyping Assay | GenomeWeb

NEW YORK (GenomeWeb) – Luminex today announced it has received a Health Canada Class 3 Device License for the xTAG CYP2D6 kit, a comprehensive in vitro diagnostic assay that analyzes a patient's cytochrome P450 2D6 (CYP2D6) genotype.                              

The test uses DNA extracted from a blood sample and runs on the Luminex 100/200 instrument. Results aid physicians in determining therapeutic strategies for patients who metabolize drugs differently because of the gene product, the firm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.